(National Institute of Mental Health)
Selecta Biosciences Inc. in Watertown, Massachusetts received a grant for $3 million from the National Institute on Drug Abuse, a part of National Institutes of Health (NIH), to advance development of an enhanced vaccine to help treat nicotine addiction and aid in smoking cessation and relapse prevention.
The grant will fund a candidate from Selecta’s drug pipeline, a nicotine vaccine, from preclinical R&D through early clinical trials. The award comes out of NIH’s Biomedical Research and Development and Growth To Spur the Acceleration of New Technologies Pilot (BRDG-SPAN) program, designed to bridge the gap between R&D and commercialization for new medical technologies.
Selecta says its technology, called tSVP, offers a new approach to a nicotine vaccine designed to boost immune responses beyond previous technologies. The tSVP approach uses nanoparticles that aim to induce highly predictable immune responses for long-lasting effects in smoking cessation.
RSS - Posts
You must be logged in to post a comment.